Reuters logo
BRIEF-Theratechnologies announces 48-week efficacy and safety results for Ibalizumab presented at IDWeek 2017(TM)
2017年10月4日 / 上午11点08分 / 14 天前

BRIEF-Theratechnologies announces 48-week efficacy and safety results for Ibalizumab presented at IDWeek 2017(TM)

Oct 4 (Reuters) - Theratechnologies Inc:

* Theratechnologies announces 48-week efficacy and safety results for Ibalizumab presented at IDWeek 2017(TM)

* Theratechnologies Inc says ‍in TMB-311, no new or unexpected safety concerns emerged between weeks 24 and 48​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below